Old disease, new targets Part-II, haematological malignancies

Shiyam Kumar, Nehal Masood, Salman Naseem Adil

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In last two decades newer therapies in cancer treatment have emerged and have opened new horizons. New term of targeted therapy has emerged and for certain malignancies the paradigm has really changed after the introduction of these agents. We have learnt and have seen the outcome of some diseases after the addition of these monoclonal antibodies (MoABs) and tyrosine kinase inhibitors (TKIs). Rituximab a MoAB against CD-20 has really paved its role in the treatment of B-cell lymphomas and become the sort of standard therapy. The TKIs are newer agents available in a pill form and have inhibited many pathways at cellular level which are necessary for cancer development. Imatinib has really changed the prognosis and outcome of chronic myeloid leukemia (CML) remarkably. For those patients who develope intolerance to imatinib or their disease became resistant to the imatinib the newer agents like dasatinib and nilotinib are second line options. The major edge of these newer agents is more potency with low side-effect profile. The major concern remains the cost.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalJournal of the Pakistan Medical Association
Volume59
Issue number8
Publication statusPublished - 2009

Fingerprint

Hematologic Neoplasms
Protein-Tyrosine Kinases
Monoclonal Antibodies
Therapeutics
Neoplasms
B-Cell Lymphoma
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Costs and Cost Analysis
Imatinib Mesylate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Old disease, new targets Part-II, haematological malignancies. / Kumar, Shiyam; Masood, Nehal; Adil, Salman Naseem.

In: Journal of the Pakistan Medical Association, Vol. 59, No. 8, 2009, p. 555-561.

Research output: Contribution to journalArticle

Kumar, Shiyam ; Masood, Nehal ; Adil, Salman Naseem. / Old disease, new targets Part-II, haematological malignancies. In: Journal of the Pakistan Medical Association. 2009 ; Vol. 59, No. 8. pp. 555-561.
@article{d0ae5459b7bb4a378009b045cc4619f2,
title = "Old disease, new targets Part-II, haematological malignancies",
abstract = "In last two decades newer therapies in cancer treatment have emerged and have opened new horizons. New term of targeted therapy has emerged and for certain malignancies the paradigm has really changed after the introduction of these agents. We have learnt and have seen the outcome of some diseases after the addition of these monoclonal antibodies (MoABs) and tyrosine kinase inhibitors (TKIs). Rituximab a MoAB against CD-20 has really paved its role in the treatment of B-cell lymphomas and become the sort of standard therapy. The TKIs are newer agents available in a pill form and have inhibited many pathways at cellular level which are necessary for cancer development. Imatinib has really changed the prognosis and outcome of chronic myeloid leukemia (CML) remarkably. For those patients who develope intolerance to imatinib or their disease became resistant to the imatinib the newer agents like dasatinib and nilotinib are second line options. The major edge of these newer agents is more potency with low side-effect profile. The major concern remains the cost.",
author = "Shiyam Kumar and Nehal Masood and Adil, {Salman Naseem}",
year = "2009",
language = "English",
volume = "59",
pages = "555--561",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "8",

}

TY - JOUR

T1 - Old disease, new targets Part-II, haematological malignancies

AU - Kumar, Shiyam

AU - Masood, Nehal

AU - Adil, Salman Naseem

PY - 2009

Y1 - 2009

N2 - In last two decades newer therapies in cancer treatment have emerged and have opened new horizons. New term of targeted therapy has emerged and for certain malignancies the paradigm has really changed after the introduction of these agents. We have learnt and have seen the outcome of some diseases after the addition of these monoclonal antibodies (MoABs) and tyrosine kinase inhibitors (TKIs). Rituximab a MoAB against CD-20 has really paved its role in the treatment of B-cell lymphomas and become the sort of standard therapy. The TKIs are newer agents available in a pill form and have inhibited many pathways at cellular level which are necessary for cancer development. Imatinib has really changed the prognosis and outcome of chronic myeloid leukemia (CML) remarkably. For those patients who develope intolerance to imatinib or their disease became resistant to the imatinib the newer agents like dasatinib and nilotinib are second line options. The major edge of these newer agents is more potency with low side-effect profile. The major concern remains the cost.

AB - In last two decades newer therapies in cancer treatment have emerged and have opened new horizons. New term of targeted therapy has emerged and for certain malignancies the paradigm has really changed after the introduction of these agents. We have learnt and have seen the outcome of some diseases after the addition of these monoclonal antibodies (MoABs) and tyrosine kinase inhibitors (TKIs). Rituximab a MoAB against CD-20 has really paved its role in the treatment of B-cell lymphomas and become the sort of standard therapy. The TKIs are newer agents available in a pill form and have inhibited many pathways at cellular level which are necessary for cancer development. Imatinib has really changed the prognosis and outcome of chronic myeloid leukemia (CML) remarkably. For those patients who develope intolerance to imatinib or their disease became resistant to the imatinib the newer agents like dasatinib and nilotinib are second line options. The major edge of these newer agents is more potency with low side-effect profile. The major concern remains the cost.

UR - http://www.scopus.com/inward/record.url?scp=68249159818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249159818&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 555

EP - 561

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 8

ER -